



BSW Formulary Updates and Recent Decisions – May 2024

New additions to BSWformulary and Change in Traffic Light Status

- **Efmody (hydrocortisone) 5mg and 10mg MR** added to formulary with **AMBER** TL for congenital adrenal hyperplasia in a small, defined cohort of [adult](#) and [paediatric](#) patients. Primary care may take on prescribing after specialist initiation and stabilisation (no sooner than 3 months).
- [Lamotrigine 10mg/ml oral suspension sugar-free](#) added with **AMBER** TL. This option is reserved for dose titrations where increments may otherwise require a partial quantity of chewable/dispersible tablet to be used/administered.
- Urea breath test kits [[Diabact Urea Breath Test](#), [Helicobacter Test INFAI adult](#) [Helicobacter Test INFAI child](#)] added to formulary with **GREEN** TL. See formulary entries for links to PHE Test and treat for Helicobacter pylori (HP) in dyspepsia QRG for primary care and for individual Summary of Product Characteristics.
- [Alfacalcidol oral capsules and drops](#) aligned with **AMBER** TL across BSW. It is the responsibility of the specialist to conduct monitoring on an individualised patient basis and communicate dose adjustments to primary care.
- [Rectal prednisolone preparations](#) – prednisolone 20mg/100ml retention enema is assigned a **GREEN** TL. Prednisolone 5mg suppositories and prednisolone 20mg foam enemas are now included with **AMBER** TL. These latter formulations are very expensive in primary care (May 2024: £249.64 for 10 suppositories and £225.45 for 14 foam applications) and we recommend they are prescribed on advice of specialist only.
- **Eylea (Aflibercept) 8mg (0.07ml of 114.5mg/ml solution)** agreed for adding to formulary with **RED** TL. Work is ongoing via BSW High-Cost Drugs group to determine approved cohort of patients to receive this strength and place in treatment pathway.

New and Updated Shared Care Agreements and Prescribing Guidance

- **BSW [SCA for Riluzole for patients within adult services](#)** – Traffic Light Status aligned to Amber with SCA. The shared care paperwork has been approved for patients across BSW based on the national SCA templates. Riluzole will be included in the updated drug LES payment agreements.
- [UPDATED BSW Community Stop Smoking Guidance](#) – Now includes cytisine; further communication about cytisine will follow next month.

Minor amendments to Netformulary

- Zacco has been included in [Prescribe Well Spend Less](#) as BSW preferred [clobazam oral solution/suspension](#). Liquid formulation should be used only where tablets are unsuitable. 10mg/5ml strength is preferred standardised strength in BSW.



- [AeroChamber Plus Flow-Vu](#) will replace the AeroChamber Plus spacer range. The Flow-Vu versions have an inspiratory flow indicator and wider range of mask sizing.

What the BSW CCG formulary team are currently working on

- Working with the ICB Childrens and Young People (CYP) asthma lead, and BSW respiratory specialists to develop local guidance for asthma in CYP. The [NICE guideline for Asthma: diagnosis, monitoring and chronic asthma management](#) (developed jointly with SIGN and BTS) has just been published in draft and the publication of this will influence timelines for local guidance.
- Reviewing the formulary status of oral glycopyrronium for various indications.
- Reviewing an application for melatonin for sleep disorders in adults with learning disability and behaviour that challenges.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net